ClinicalTrialsFinder
RecruitingNCT03573791

Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer

Identification of Tissue Biomarkers for Predicting Neoadjuvant Chemoradio-resistance in Patients With Middle-low Local Advanced Rectal Cancer.

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Enrollment

152 participants

Start Date

May 21, 2018

Study Type

OBSERVATIONAL

Conditions

Rectal CancerRectum CancerCancer of RectumCancer of the RectumNeoplasms, RectalRectal TumorsRectum Neoplasms

Summary

Neoadjuvant therapy has been widely applied to locally advanced rectal cancer. However, about 50% of patients receiving this therapy do not respond well as evidenced by the fact that their T or N stages are not effectively decreased judged by postoperative pathological examination. The purpose of this trail is to identify the biomarkers (from within patients' tumor mass before neoadjuvant therapy) to predict resistance to neoadjuvant therapy. These biomarkers can help stratify neoadjuvant-resistant patients towards surgery while avoiding unnecessary chemoradio-based neoadjuvant therapy.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study looks for biological markers in tumor samples that can predict whether a patient with rectal cancer will respond well to chemotherapy and radiation treatment given before surgery (called neoadjuvant chemoradiation), helping doctors better personalize treatment plans. **You may be eligible if...** - You have been confirmed by biopsy to have rectal cancer (adenocarcinoma of the rectum) - Your tumor is within 12 cm of the anal opening - Your cancer is at an advanced local stage (Stage II or III: T3–T4 or with lymph node involvement) - You have not previously had chemotherapy, radiation, or immunotherapy for this cancer - You are willing to sign the informed consent form **You may NOT be eligible if...** - Your bowel is blocked or perforated by the tumor - You have had another cancer within the past 5 years Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(2)

Wuhan Union Hospital

Wuhan, Hubei, China

Hubei Cancer Hospital

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03573791

Related Trials

Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

NCT068500901 location

Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy

NCT075610601 location

Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer

NCT075282091 location

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

NCT031909411 location

Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer

NCT046430411 location